Proceedings of the 93rd American Association for Cancer Research Annual Meeting, April 6-10, 2002, San Francisco, California. Philadelphia, PA: American Association for Cancer Research, 2002 Apr; 43:634
In an attempt to identify chromosomal changes that may be involved with invasive and/or metastatic properties, we used Spectral Karyotyping to analyze nine pairs of high and low invasive tumor cell cultures derived from early passage (3 to 5 passages from the primary tumor) mouse lung adenocarcinoma cell lines. The high and low invasive cultures were obtained by a Gel Matrix technique. The cells with high invasive property penetrate the gel matrix while the cells with low invasive property remain on the surface. Seven of the nine original lung adenocarcinomas were from the A/J mouse, a strain highly susceptible to lung carcinoma. Two of the nine original lung adenocarcinomas were from B6C3F1 mice, an F1 hybrid resulting from a cross between two resistant strains, C57BU6J and C3H/Hen. At least twenty metaphase spreads were observed for each culture: A chromosomal event that occurred in over 40% of the cells from a specific culture was scored as a positive event. Regression Tree analysis showed that duplication of chromosome 1 is significant in high invasive cultures (9/9) compared to low invasive cultures (3/9). Mapping with fluorescent labeled genomic probes identified the minimal region of duplication to be 73 to 94 centimorgan on chromosome 1, which includes a candidate Cyclooxyenase 2 (C0X2) gene. Further study for the expression of C0X2 is under investigation. Duplication of chromosome 15 was also found to be significantly higher in high invasive (8/9) than in low invasive (4/9) cultures. Our results indicate that chromosome 1 and 15 may be involved with the invasiveness and the candidate genes on these chromosome regions may play role for invasive and/or metastatic properties.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.